Hormone replacement therapy and cancer: An update

European Journal of Cancer Prevention

Volumn 12, Issue 1, 2003, Pages 3-4

  La Vecchia, C ^a,b   Franceschi, S ^c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; EDITORIAL; ENDOMETRIUM CANCER; EPIDEMIOLOGICAL DATA; FOLLOW UP; HEALTH CARE ORGANIZATION; HORMONE SUBSTITUTION; HUMAN; MENOPAUSE; OVARY CANCER; PRIMARY PREVENTION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE;

AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIDDLE AGED; OVARIAN NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT;

EID: 0037329854     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008469-200302000-00002     Document Type: Editorial

References (12)

1. Beral V, Banks E, Reeves G (2002). Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360:942-944.
2. Beral V, Banks E, Reeves G, Appleby P (1999). Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 4:191-215.
3. Bosetti C, Negri E, Franceschi S, et al. (2001). Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285:3089.
4. Collaborative Group on Hormonal Factors in Breast Cancer (1997). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350:1047-1059.
5. Herbert-Croteau N (1998). A meta-analysis of hormone replacement therapy and colon cancer among women. Cancer Epidemiol Biomarkers Prev 7:653-659.
6. Hulley S, Furberg C, Barrett-Connor E, et al. (2002). Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:58-66.
7. IARC (1999). Monographs on the Evaluation of the Carcinogenic Risks to Humans, Vol. 72, Hormonal Contraception and Post-Menopausal Hormonal Therapy. Lyon, France: International Agency for Research on Cancer.
8. La Vecchia C, Brinton LA, McTiernan A (2001). Menopause, hormone replacement therapy and cancer. Maturitas 39:97-115.
9. Lacey JV, Mink PJ, Lubin JH, et al. (2002). Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288:334-341.
10. Schairer C, Lubin J, Troisi R, et al. (2000). Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283:485-491.
11. Viscoli CM, Brass LM, Kernan WN, et al. (2001). A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345:1243-1249.
12. Writing Group for the Women's Health Initiative Investigators (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.